Published: May 12, 2026 at 5:13 pm
Isomorphic Labs, an AI-first drug design and development company founded by DeepMind founder Sir Demis Hassabis, has raised £1.6 billion in Series B funding.
The latest round of investment will accelerate the UK company’s evolution from pioneering novel AI models to applying them at scale.
The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base.